{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-002761","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-18T12:33:17+00:00","discovered_at":"2026-05-18T12:35:00.473488+00:00","generated_at":"2026-05-18T12:35:42.540071+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silexion Therapeutics Q1 net loss $2.7M; cash $2.4M; Phase 2/3 trial on track for Q2 2026","bullets":["Net loss of $2.7M for Q1 2026 vs $1.7M in Q1 2025; R&D expenses rose 133% to $1.4M driven by trial preparation.","Cash and equivalents $2.4M at Mar 31, 2026, down from $6.0M at Dec 31, 2025; post-quarter capital raises of $1.0M from warrant inducement.","Israeli Ministry of Health approved Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer; CTA submitted to Germany.","Phase 2/3 trial initiation remains on track for Q2 2026 with safety run-in of ~18 patients, then randomized cohort of ~166.","Company believes post-quarter equity transactions restored Nasdaq compliance with $2.5M minimum shareholders' equity requirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002761","json":"https://secwatch.observer/filing/0001178913-26-002761.json","markdown":"https://secwatch.observer/filing/0001178913-26-002761.md","text":"https://secwatch.observer/filing/0001178913-26-002761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/0001178913-26-002761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/zk2635360.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T12:35:42.540071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f40104c0156906bd7ac66413538840254746eddd","claim":"Silexion Therapeutics Corp reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026, was approximately $2.7 million.","evidence_excerpt":"On May 18, 2026, Silexion Therapeutics Corp issued a press release announcing its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/0001178913-26-002761-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2026, was approximately $2.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}